Comparative analysis of the efficacy of conbercept or ranibizumab combined with laser photocoagulation in the treatment of retinal vein occlusion with macular edema
Objective To compare and analyze the clinical effect of conbercept or ranibizumab combined with laser photocoagulation in the treatment of retinal vein occlusion (RVO) with macular edema (ME). Methods A total of 87 patients with RVO and ME admitted to Lishui Central Hospital,from January 2022 to November 2023 were selected and divided into a conbercept group (treated with conbercept combined with laser photocoagu-lation,n=46) and a ranibizumab group (treated with ranibizumab combined with laser photocoagulation,n=41) based on different treatment methods. After 3 months of treatment,the best corrected visual acuity (BCVA),central macular thickness (CMT),levels of inflammatory factors[vascular endothelial growth factor (VEGF),monocyte chemoattractant protein-1 (MCP-1),and interleukin-6 (IL-6)],occurrence of complications,and rate of repeat med-ication were evaluated in both groups. Results After 1,2,and 3 months of treatment,the BCVA and CMT grad-ually decreased in both groups (P<0.05),but there were no significant differences between the groups (P>0.05). The levels of VEGF,MCP-1,and IL-6 decreased after treatment in both groups (P<0.05),with no significant dif-ferences between the groups (P>0.05). The total incidence of complications was 8.7％in the conbercept group and 12.2％ in the ranibizumab group,with no significant difference between the two groups (P>0.05). The rate of re-peated medication was 2.2％ in the conbercept group,which was lower than the 14.6％ in the ranibizumab group (P<0.05). Conclusion Both conbercept and ranibizumab,each combined with laser photocoagulation,are treat-ment options for RVO with ME. They exhibit similar efficacy,improving patients' visual acuity,alleviating macular edema,and reducing inflammatory cytokine levels,with low complication rates and high safety.
万方数据
维普
